

	Clinical trials combined	Real clinical use in UK (ABCD audit)
	Baseline HbA _{1c} (%)	
Exenatide	8.37	9.47
Liraglutide	8.5	9.40
	Baseline BMI (kg/m ²)	
Exenatide	32.72	39.8
Liraglutide	31	39.0

Table: In real clinic practice in the UK patients had far worse glycaemic control and were much heavier than patients treated in clinical trials. From the presentation “ABCD Nationwide Exenatide and Liraglutide Audits” by Dr Bob Ryder and Professor Stephen Gough on behalf of the ABCD nationwide exenatide and liraglutide audit contributors. Scientific Update Satellite Meeting - IDF Dubai 6 December 2011. See:

http://www.diabetologists-abcd.org.uk/GLP1_Audits/IDF_Dubai2011_SUM.pdf